Literature DB >> 30185599

Persistent Replication of HIV, Hepatitis C Virus (HCV), and HBV Results in Distinct Gene Expression Profiles by Human NK Cells.

Lauke L Boeijen1, Jun Hou2, Rik A de Groen2, Annelies Verbon3, André Boonstra2.   

Abstract

Natural killer (NK) cells during chronic viral infection have been well studied in the past. We performed an unbiased next-generation RNA-sequencing approach to identify commonalities or differences of the effect of HIV, HCV, and HBV viremia on NK cell transcriptomes. Using cell sorting, we obtained CD3- CD56+ NK cells from blood of 6 HIV-, 8 HCV-, and 32 HBV-infected patients without treatment. After library preparation and sequencing, we used an in-house analytic pipeline to compare expression levels with matched healthy controls. In NK cells from HIV-, HCV-, and HBV-infected patients, transcriptome analysis identified 272, 53, and 56 differentially expressed genes, respectively (fold change, >1.5; q-value, 0.2). Interferon-stimulated genes were induced in NK cells from HIV/HCV patients, but not during HBV infection. HIV viremia downregulated ribosome assembly genes in NK cells. In HBV-infected patients, viral load and alanine aminotransferase (ALT) variation had little effect on genes related to NK effector function. In conclusion, we compare, for the first time, NK cell transcripts of viremic HIV, HCV, and HBV patients. We clearly demonstrate distinctive NK cell gene signatures in three different populations, suggestive for a different degree of functional alterations of the NK cell compartment compared to healthy individuals.IMPORTANCE Three viruses exist that can result in persistently high viral loads in immunocompetent humans: human immunodeficiency virus (HIV), hepatitis C virus, and hepatitis B virus. In the last decades, by using flow cytometry and in vitro assays on NK cells from patients with these types of infections, several impairments have been established, particularly during and possibly contributing to HIV viremia. However, the background of NK cell impairments in viremic patients is not well understood. In this study, we describe the NK cell transcriptomes of patients with high viral loads of different etiologies. We clearly demonstrate distinctive NK cell gene signatures with regard to interferon-stimulated gene induction and the expression of genes coding for activation markers or proteins involved in cytotoxic action, as well immunological genes. This study provides important details necessary to uncover the origin of functional and phenotypical differences between viremic patients and healthy subjects and provides many leads that can be confirmed using future in vitro manipulation experiments.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  hepatitis B virus; hepatitis C virus; human immunodeficiency virus; natural killer cells

Mesh:

Year:  2019        PMID: 30185599      PMCID: PMC6475777          DOI: 10.1128/JVI.00575-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals.

Authors:  Jihed Chehimi; Donald E Campbell; Livio Azzoni; Darlene Bacheller; Emmanouil Papasavvas; Ghassen Jerandi; Karam Mounzer; Jay Kostman; Giorgio Trinchieri; Luis J Montaner
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

2.  Role of IRF4 in IFN-stimulated gene induction and maintenance of Kaposi sarcoma-associated herpesvirus latency in primary effusion lymphoma cells.

Authors:  Adriana Forero; Patrick S Moore; Saumendra N Sarkar
Journal:  J Immunol       Date:  2013-06-26       Impact factor: 5.422

3.  Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF).

Authors:  Eric T T L Tjwa; Roeland Zoutendijk; Gertine W van Oord; Lauke L Boeijen; Jurrien G P Reijnders; Margo J H van Campenhout; Robert J de Knegt; Harry L A Janssen; Andrea M Woltman; Andre Boonstra
Journal:  Antiviral Res       Date:  2016-05-27       Impact factor: 5.970

4.  Compromised function of natural killer cells in acute and chronic viral hepatitis.

Authors:  Sebastian Lunemann; David F G Malone; Julia Hengst; Kerstin Port; Jan Grabowski; Katja Deterding; Antoaneta Markova; Birgit Bremer; Verena Schlaphoff; Markus Cornberg; Michael P Manns; Johan K Sandberg; Hans-Gustaf Ljunggren; Niklas K Björkström; Heiner Wedemeyer
Journal:  J Infect Dis       Date:  2013-10-23       Impact factor: 5.226

Review 5.  Innate and Adaptive Immune Regulation During Chronic Viral Infections.

Authors:  Elina I Zuniga; Monica Macal; Gavin M Lewis; James A Harker
Journal:  Annu Rev Virol       Date:  2015-09-02       Impact factor: 10.431

6.  Defective killing activity against gp120/41-expressing human erythroleukaemic K562 cell line by monocytes and natural killer cells from HIV-infected individuals.

Authors:  A Ahmad; J Menezes
Journal:  AIDS       Date:  1996-02       Impact factor: 4.177

7.  Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.

Authors:  Golo Ahlenstiel; Rachel H Titerence; Christopher Koh; Birgit Edlich; Jordan J Feld; Yaron Rotman; Marc G Ghany; Jay H Hoofnagle; T Jake Liang; Theo Heller; Barbara Rehermann
Journal:  Gastroenterology       Date:  2009-09-10       Impact factor: 22.682

8.  Phosphorylation of HIV Tat by PKR increases interaction with TAR RNA and enhances transcription.

Authors:  Liliana Endo-Munoz; Tammra Warby; David Harrich; Nigel A J McMillan
Journal:  Virol J       Date:  2005-02-28       Impact factor: 4.099

9.  Causal analysis approaches in Ingenuity Pathway Analysis.

Authors:  Andreas Krämer; Jeff Green; Jack Pollard; Stuart Tugendreich
Journal:  Bioinformatics       Date:  2013-12-13       Impact factor: 6.937

10.  Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection.

Authors:  Behzad Hajarizadeh; François Mj Lamoury; Jordan J Feld; Janaki Amin; Elizabeth Keoshkerian; Gail V Matthews; Margaret Hellard; Gregory J Dore; Andrew R Lloyd; Jason Grebely; Tanya L Applegate
Journal:  Virol J       Date:  2016-02-24       Impact factor: 4.099

View more
  4 in total

Review 1.  Gene Expression: the Key to Understanding HIV-1 Infection?

Authors:  Melinda Judge; Erica Parker; Denise Naniche; Peter Le Souëf
Journal:  Microbiol Mol Biol Rev       Date:  2020-05-13       Impact factor: 11.056

2.  An integrative genomic analysis of transcriptional profiles identifies characteristic genes and patterns in HIV-infected long-term non-progressors and elite controllers.

Authors:  Jiwei Ding; Ling Ma; Jianyuan Zhao; Yongli Xie; Jinming Zhou; Xiaoyu Li; Shan Cen
Journal:  J Transl Med       Date:  2019-01-21       Impact factor: 5.531

3.  Peripheral natural killer cells in chronic hepatitis B patients display multiple molecular features of T cell exhaustion.

Authors:  Marie Marotel; Marine Villard; Annabelle Drouillard; Issam Tout; Laurie Besson; Omran Allatif; Marine Pujol; Yamila Rocca; Michelle Ainouze; Guillaume Roblot; Sébastien Viel; Melissa Gomez; Veronique Loustaud; Sophie Alain; David Durantel; Thierry Walzer; Uzma Hasan; Antoine Marçais
Journal:  Elife       Date:  2021-01-28       Impact factor: 8.140

4.  Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes.

Authors:  Tony Wawina-Bokalanga; Bert Vanmechelen; Valentine Lhermitte; Joan Martí-Carreras; Valentijn Vergote; Fara Raymond Koundouno; Joseph Akoi-Boré; Ruth Thom; Tom Tipton; Kimberley Steeds; Kéita Balla Moussa; Ablam Amento; Lies Laenen; Sophie Duraffour; Martin Gabriel; Paula Ruibal; Yper Hall; Mandy Kader-Kondé; Stephan Günther; Guy Baele; Cesar Muñoz-Fontela; Johan Van Weyenbergh; Miles W Carroll; Piet Maes
Journal:  Emerg Infect Dis       Date:  2021-01       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.